Patents matching “ala”

US 9763974

Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase

GALECTIN THERAPEUTICS, INC. · Granted Sep 19, 2017 · Expires Sep 14, 2037

US 9737478

Treatment of malaria

National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), The United States of America NIH Division of Extramural Inventions and Technology Resources (DEITR) · Granted Aug 22, 2017 · Expires Aug 17, 2037

US 9732333

Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells

Protalix Ltd. · Granted Aug 15, 2017 · Expires Aug 10, 2037

US 9708595

Stabilized alpha-galactosidase and uses thereof

Protalix Ltd. · Granted Jul 18, 2017 · Expires Jul 13, 2037

US 9707295

Inhalable medicament

Teva Branded Pharmaceutical Products R&D, Inc. · Granted Jul 18, 2017 · Expires Jul 13, 2037

US 9707252

Synthetic sealants

Covidien LP · Granted Jul 18, 2017 · Expires Jul 13, 2037

US 9700562

Triazine compounds and compositions thereof and methods for treating malaria and chemoprophylaxis

The United States of America, as represented by the Secretary of the Army, on behalf of the Walter Reed Army Institute of Research · Granted Jul 11, 2017 · Expires Jul 6, 2037

US 9682969

Phthalazinone compounds and methods for the treatment of cystic fibrosis

Flatley Discovery Lab, LLC · Granted Jun 20, 2017 · Expires Jun 15, 2037

US 9655969

Inhalable medicament comprising tiotropium

Teva Branded Pharmaceutical Products R&D, Inc. · Granted May 23, 2017 · Expires May 18, 2037

WO 2017072335

UTILISATION DE MASITINIB ET D'AUTRES INHIBITEURS DE MASTOCYTE POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON

AB SCIENCE [FR] · Granted May 4, 2017 · Expires Apr 29, 2037

US 9631193

Compositions and methods for inhibiting expression of the ALAS1 gene

Alnylam Pharmaceuticals, Inc. · Granted Apr 25, 2017 · Expires Apr 20, 2037

US 9603906

Inhalable liquid formulations of DNase I

Protalix Ltd. · Granted Mar 28, 2017 · Expires Mar 23, 2037

US 9592271

Angiopoietin-based interventions for treating cerebral malaria

REGENERON PHARMACEUTICALS, INC. · Granted Mar 14, 2017 · Expires Mar 9, 2037

US 9580438

Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders

4SC DISCOVERY GMBH · Granted Feb 28, 2017 · Expires Feb 23, 2037

US 9567572

Manufacture of active highly phosphorylated human N-acetylgalactosamine-6-sulfatase and uses thereof

BIOMARIN PHARMACEUTICAL INC. · Granted Feb 14, 2017 · Expires Feb 9, 2037

WO 2017013210

TRAITEMENT ET PRÉVENTION DE MALADIES VIRALES AVEC DES COMPOSÉS DE 2,3-DIHYDROBENZOFURAN-5-YL

4SC AG [DE] · Granted Jan 26, 2017 · Expires Jan 21, 2037

US 9546368

Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1 (MALAT-1) expression

Ionis Pharmaceuticals, Inc. · Granted Jan 17, 2017 · Expires Jan 12, 2037

US 9463166

Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride

RECRO GAINESVILLE LLC · Granted Oct 11, 2016 · Expires Oct 6, 2036

US 9422347

Algal produced malarial transmission blocking vaccines

The Regents of the University of California · Granted Aug 23, 2016 · Expires Aug 18, 2036

US 9394316

Inhibitors of the plasmodial surface anion channel as antimalarials

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jul 19, 2016 · Expires Jul 14, 2036

US 9375424

Compounds that treat malaria and prevent malaria transmission

The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Jun 28, 2016 · Expires Jun 23, 2036

US 9364540

Inhalable medicament

Teva Branded Pharmaceutical Products R&D, Inc. · Granted Jun 14, 2016 · Expires Jun 9, 2036

US 9358240

Treprostinil administration by inhalation

United Therapeutics Corporation · Granted Jun 7, 2016 · Expires Jun 2, 2036

US 9339507

Treprostinil administration by inhalation

United Therapeutics Corporation · Granted May 17, 2016 · Expires May 12, 2036